Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 275 of 348 entries
View as:

Safety Study of a Single Dose of REGN88(SAR153191)in Patients With Rheumatoid Arthritis

Phase: N/A Priority: Normal
NCT ID: NCT01055899 Org: User:
Start: 07/31/08 End: 03/31/09 Due: 03/31/10

Study of Nesvacumab (REGN910/ SAR307746)

Phase: N/A Priority: Normal
NCT ID: NCT01271972 Org: User:
Start: 01/31/11 End: 05/31/15 Due: 05/31/16

Study of Dupilumab in Adult Participants With Active Eosinophilic Esophagitis (EoE)

Phase: N/A Priority: Normal
NCT ID: NCT02379052 Org: User:
Start: 05/12/15 End: 07/10/17 Due: 07/10/18

Ascending Dose Study of the Safety and Tolerability of REGN668(SAR231893) in Normal Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT01015027 Org: User:
Start: 10/31/09 End: 07/31/10 Due: 07/31/11

A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery

Phase: N/A Priority: Normal
NCT ID: NCT05608291 Org: User:
Start: 01/16/23 End: 02/15/30 Due: 02/15/31

R3470-3471-3479 (REGN-EB3) Expanded Access Protocol (EAP) for Treatment of Ebola Virus Disease

Phase: N/A Priority: Normal
NCT ID: NCT03576690 Org: User:
Start: - End: - Due: -

Long-Term Safety and Efficacy Study of Fasinumab in Patients With Pain Due to Osteoarthritis (OA) of the Knee or Hip

Phase: N/A Priority: Normal
NCT ID: NCT02683239 Org: User:
Start: 02/17/16 End: 06/15/21 Due: 06/15/22

COVID-19 Study to Assess Immunogenicity, Safety, and Tolerability of Moderna mRNA-1273 Vaccine Administered With Casirivimab+Imdevimab in Healthy Adult Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT04852978 Org: User:
Start: 04/29/21 End: 11/21/22 Due: 11/21/23

Study of the Efficacy and Safety of Intravitreal (IVT) Aflibercept for the Improvement of Moderately Severe to Severe Nonproliferative Diabetic Retinopathy (NPDR)

Phase: N/A Priority: Normal
NCT ID: NCT02718326 Org: User:
Start: 03/29/16 End: 07/16/19 Due: 07/16/20

A Study to Examine the Efficacy and Safety of Anti-Fel d 1 Antibodies Injections in Cat-allergic Adolescent and Adult Patients With Allergic Rhinitis Who Live With a Cat

Phase: N/A Priority: Normal
NCT ID: NCT04981717 Org: User:
Start: 07/30/21 End: 04/24/23 Due: 04/24/24

REGN3918 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate Its Long Term Safety, Efficacy and Tolerability.

Phase: N/A Priority: Normal
NCT ID: NCT04162470 Org: User:
Start: 12/03/19 End: 04/07/22 Due: 04/07/23

A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04916002 Org: User:
Start: 11/30/21 End: 10/31/24 Due: 10/31/25

Efficacy and Safety of Dupilumab in Participants ≥12 to <18 Years of Age, With Moderate-to-severe Atopic Dermatitis

Phase: N/A Priority: Normal
NCT ID: NCT03054428 Org: User:
Start: 03/21/17 End: 06/05/18 Due: 06/05/19

A Trial to Learn if Single Ascending Intravenous (IV) Doses of REGN7508 Are Safe and Well Tolerated, and How it Works in the Body of Healthy Adult Participants

Phase: N/A Priority: Normal
NCT ID: NCT05603195 Org: User:
Start: 01/12/23 End: 09/17/24 Due: 09/17/25

A Study of the Safety and Efficacy of Subcutaneously Administered REGN475 in Patients With Osteoarthritis of the Knee

Phase: N/A Priority: Normal
NCT ID: NCT01239017 Org: User:
Start: - End: - Due: -

A Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Injected Under the Skin for the Treatment of Iron Overload in Adult Participants With Non-Transfusion Dependent β-thalassemia, Using MRI Scans to Measure Iron Levels in the Body

Phase: N/A Priority: Normal
NCT ID: NCT06421636 Org: User:
Start: 09/30/24 End: 01/24/28 Due: 01/24/29

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of REGN9035 in Healthy Adult Volunteers and Mildly Hypertensive Participants

Phase: N/A Priority: Normal
NCT ID: NCT05291546 Org: User:
Start: 04/13/22 End: 04/02/24 Due: 04/02/25

Ascending Dose Study of the Safety and Tolerability of REGN6490 in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT04616079 Org: User:
Start: 11/19/20 End: 06/01/21 Due: 06/01/22

Study to Assess the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Compared to Laser Photocoagulation in Patients With Retinopathy of Prematurity

Phase: N/A Priority: Normal
NCT ID: NCT04101721 Org: User:
Start: 10/30/19 End: 08/18/22 Due: 08/18/23

A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers

Phase: N/A Priority: Normal
NCT ID: NCT06469281 Org: User:
Start: 07/18/24 End: 06/29/29 Due: 06/29/30

Efficacy of the Anti-Bet v 1 Monoclonal Antibodies (Given Subcutaneously) to Reduce Allergic Rhinitis and Conjunctivitis Symptoms and Skin Test Reactivity Upon Exposure to Birch Allergen in Adult Participants

Phase: N/A Priority: Normal
NCT ID: NCT05430919 Org: User:
Start: 08/15/22 End: 07/31/23 Due: 07/31/24

Safety, Tolerability, and Pharmacokinetics of REGN5069 in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT03645746 Org: User:
Start: 08/23/18 End: 09/30/19 Due: 09/30/20

Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic Dermatitis

Phase: N/A Priority: Normal
NCT ID: NCT02260986 Org: User:
Start: 09/30/14 End: 10/31/16 Due: 10/31/17

Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT05352672 Org: User:
Start: 07/14/22 End: 06/30/31 Due: 06/30/32

A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT06140524 Org: User:
Start: 09/16/24 End: 05/18/32 Due: 05/18/33